Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 2022; 10(27): 9714-9726 [PMID: 36186213 DOI: 10.12998/wjcc.v10.i27.9714]
Corresponding Author of This Article
Zheng-Xu Wang, MD, PhD, Professor, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, No. 5 Nanmencang Road, Dongcheng District, Beijing 100700, China. zhxuwang@qq.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 26, 2022; 10(27): 9714-9726 Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9714
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo, Zheng-Xu Wang
Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo, Zheng-Xu Wang, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China
Author contributions: Cao JX and Wang ZX conceived and designed the meta-analysis; Cao JX and Wang ZX performed the experiments; Cao JX, Wu LH, You J and Luo K analyzed the data; Cao JX and Wang ZX wrote the paper; All authors have read and approved the manuscript.
Supported byScientific Research Projects in China, No. CLB19J053 and 19SWAQ13.
Conflict-of-interest statement: The authors indicate no potential conflicts of interest.
PRISMA 2009 Checklist statement: The manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Xu Wang, MD, PhD, Professor, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, No. 5 Nanmencang Road, Dongcheng District, Beijing 100700, China. zhxuwang@qq.com
Received: May 6, 2022 Peer-review started: May 6, 2022 First decision: June 11, 2022 Revised: June 26, 2022 Accepted: August 21, 2022 Article in press: August 21, 2022 Published online: September 26, 2022 Processing time: 124 Days and 23.2 Hours
ARTICLE HIGHLIGHTS
Research background
Currently, ongoing trials of mesenchymal stem cell therapies for coronavirus disease 2019 (COVID-19) have been reported.
Research motivation
Whether mesenchymal stem cells have therapeutic efficacy in novel COVID-19 patients.
Research objectives
Clinical trials were published with stem cells therapy in COVID-19 patients.
Research methods
Mantel and Haenszel meta-analysis (Review Manager Version 5.0, Nordic Cochran Centre, Copenhagen) was used for data analysis.
Research results
There was a significant improvement in overall survival (OS) after stem cell therapy; the OS of enrolled patients who received stem cell therapy was 90.3%, whereas that of the control group was 79.8% (P = 0.02).
Research conclusions
Mesenchymal stem cells therapy for COVID-19 patients does not significantly decrease inflammatory markers such as C-reactive protein, D-dimer and interleukin 6, OS is improved.
Research perspectives
Stem cell therapy for COVID-19 patients will become a realistic goal in the foreseeable future.
